Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Optibiotix and Knighton's to launch improved version of microbiome-based appetite suppressant Slimbiome

Knighton’s tehcnology will make SlimBiome easier to dissolve and enhancing its ease of use, flavour and mouthfeel
tape measure
Slimbiome enourages fat loss rather than just weight

Microbiome pioneer OptiBiotix Health PLC (LON:OPTI) will launch its revised formulation of hunger suppressant product SlimBiome, using a powder technology developed by new partner Knighton’s.

Knighton’s tehcnology will make SlimBiome easier to dissolve and enhances its ease of use, flavour and mouthfeel, said Optibiotix, and will open opportunities in bakeries, snacking, coffee shops and the growing ‘shakes’ market.

WATCH: Massive opportunities for OptiBiotix Health's new and improved SlimBiome

SlimBiome will be sold as an ingredient in white label format and will be highlighted in OptiBiotix's own brand the GoFigure range of shakes and bars.

AIM-listed Optibiotix wants to target the growing  'Health & Wellbeing' lifestyle trend and sees a huge possible range of applications with new flavours and applications such as muesli.

Knighton’s, part of Premier Foods, is one of a number partners that are using Slimbiome to develop products such as cookies, tortillas, breakfast cereals, food toppings, yoghurts and cereal bars.

Eventually, the plan is to ‘white label’ Slimbiome to large retailers, and branded consumer products manufacturers as well as food manufacturers.

READ: OptiBiotix licenses weight-loss technology to Premier Foods offshoot

Slimbiome has been developed from Optibiotix’s work on the human microbiome, the bacteria that inhabits the gut and skin and that is increasingly being recognised as playing a critical part in the way the human body processes food.

 Stephen O'Hara, Optibiotix chief executive, said: “We anticipate SlimBiome being the first in a family of products to include: ImmunBiome, WellBiome, OptiBiome and CardioBiome, developed using our advanced microbiome modulating technology platforms.”

 

 

View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
man at a micrscope
September 29 2017
The company is a specialist in the storage of stems cells from the umbilical cord, which could provide a potentially life-saving treatment for 82 blood-borne diseases
Workers at CERN
September 29 2017
The technology being developed is cheaper and smaller than the current units, which are almost prohibitively expensive

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use